Massoud Shayestehazar; MH Karimi nasab; M Razavi pour; S Jour Ebrahimian
Abstract
AbstractBackground: Osteoporosis is the most common bone metabolic disease. The purpose of this study was to evaluate the effect of anti-osteoporosis treatment with bisphosphonate and parathyroid on bone repair in patients with osteoporosis related fractures.Methods: This single-blind randomized controlled ...
Read More
AbstractBackground: Osteoporosis is the most common bone metabolic disease. The purpose of this study was to evaluate the effect of anti-osteoporosis treatment with bisphosphonate and parathyroid on bone repair in patients with osteoporosis related fractures.Methods: This single-blind randomized controlled clinical trial was performed on three groups of 20 patients each (parathyroid hormone, alendronate and control) with osteoporosis fractures hospitalized in orthopedic ward of Emam Khomeini and Boali Sinaye Sari hospitals during 2016-2018. All the patients were assessed at the 4th, 8th, and 12th week in terms of union.Results: While no union was reported at the end of the fourth week, 20, 18, and 17 subjects respectively on CinnoPar, alendronate and control groups had union at the end of the eighth week. Furthermore, the complete union was achieved for all patients in the 12th week.Conclusions: According to the results of the study, no significant difference was observed in the repair of osteoporotic fractures of distal radius by alendronate and parathyroid hormone.
